Chronic Metformin Administration Does Not Alter Carotid Sinus Nerve Activity in Control Rats

Adv Exp Med Biol. 2023:1427:203-208. doi: 10.1007/978-3-031-32371-3_22.

Abstract

Metformin is a glucose-lowering, insulin-sensitizing drug that is commonly used in the treatment of type 2 diabetes (T2D). In the last decade, the carotid body (CB) has been described as a metabolic sensor implicated in the regulation of glucose homeostasis, being CB dysfunction crucial for the development of metabolic diseases, such as T2D. Knowing that metformin could activate AMP-activated protein kinase (AMPK) and that AMPK has been described to have an important role in CB hypoxic chemotransduction, herein we have investigated the effect of chronic metformin administration on carotid sinus nerve (CSN) chemosensory activity in basal and hypoxic and hypercapnic conditions in control animals. Experiments were performed in male Wistar rats subjected to 3 weeks of metformin (200 mg/kg) administration in the drinking water. The effect of chronic metformin administration was tested in spontaneous and hypoxic (0% and 5% O2) and hypercapnic (10% CO2) evoked CSN chemosensory activity. Metformin administration for 3 weeks did not modify the basal CSN chemosensory activity in control animals. Moreover, the CSN chemosensory response to intense and moderate hypoxia and hypercapnia was not altered by the chronic metformin administration. In conclusion, chronic metformin administration did not modify chemosensory activity in control animals.

Keywords: Carotid body; Carotid sinus nerve; Hypercapnia; Hypoxia; Metformin.

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Animals
  • Carotid Body* / physiology
  • Carotid Sinus / innervation
  • Carotid Sinus / metabolism
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetes Mellitus, Type 2* / metabolism
  • Hypercapnia
  • Hypoxia
  • Male
  • Metformin* / pharmacology
  • Rats
  • Rats, Wistar

Substances

  • Metformin
  • AMP-Activated Protein Kinases